Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate (PCS-VI)

NCT02303327 is registered in ClinicalTrials.gov with Sir Mortimer B. Davis - Jewish General Hospital as lead sponsor.

NCT NCT02303327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02303327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate (PCS-VI)
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 31, 2015
Completion date
January 31, 2029
Enrollment
307 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer